Volume 74, Issue 3 pp. 1716-1717
Correspondence

Letter to the Editor: Oral Vancomycin Versus No Therapy for Pediatric Primary Sclerosing Cholangitis

Kevin M. Johnson M.D.

Kevin M. Johnson M.D.

Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, CT

Search for more papers by this author
Ryan T. Fischer M.D.

Ryan T. Fischer M.D.

Division of Hepatology and Transplant Medicine, Department of Gastroenterology, Children’s Mercy Hospital, Kansas City, MO

Search for more papers by this author
Gerald J. Holtmann M.D., Ph.D.

Gerald J. Holtmann M.D., Ph.D.

Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, and University of Queensland, Brisbane, Queensland, Australia

Search for more papers by this author
Ayesha Shah M.B.B.S.

Ayesha Shah M.B.B.S.

Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, and University of Queensland, Brisbane, Queensland, Australia

Search for more papers by this author
Leina Alrabadi M.D.

Leina Alrabadi M.D.

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Stanford University School of Medicine, Palo Alto, CA

Search for more papers by this author
Peter Lewindon M.B.B.S.

Peter Lewindon M.B.B.S.

Department of Gastroenterology, Queensland Children’s Hospital, and Children’s Medical Research Institute, University of Queensland, Brisbane, Queensland, Australia

Search for more papers by this author
First published: 26 February 2021
Potential conflict of interest: Dr. Lewindon is on the speakers’ bureau for AbbVie, Pfizer and Janssen-Cilag.
No abstract is available for this article.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.